REAL-WORLD CHARACTERISTICS, TREATMENT PATHWAYS AND HEALTHCARE RESOURCE USE IN PATIENTS TREATED FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN SPAIN: PRELIMINARY RESULTS FROM THE PREMIERE STUDY
(Abstract release date: 05/19/16)
EHA Library. Zagorska A. 06/09/16; 134997; PB2097
Dr. Aleksandra Zagorska
Contributions
Contributions
Abstract
Abstract: PB2097
Type: Publication Only
Background
The management of patients (pts) with multiple myeloma (MM) has changed considerably in recent years. Pts’ life expectancy has significantly increased, and in some cases MM is now considered a chronic disease, with pts receiving multiple lines of therapies. Real-world data on health and resource-related outcomes of different treatment patterns may help promote more efficient resource allocation within the National Health System.
Aims
To describe baseline characteristics, treatment patterns and healthcare resource utilization (HCRU) in a cohort of pts treated for relapsed refractory (RR) MM in Spain.
Methods
The PREMIERE study is a retrospective chart review study conducted in a representative cohort of pts with RRMM in Spain. Enrolled pts were aged ≥18 years, had ≥1 prior treatment for MM, and began a new line of therapy (index therapy) during the recruitment period of 1st July 2010–30th June 2012 due to relapsing or refractory disease. Pts were followed from initiation of index therapy (index date) for 3 years, or until death, loss to follow-up, or enrollment into a clinical trial for MM. Using an interim data extraction from November 30th 2015, descriptive statistics of pt characteristics at initiation of index therapy were calculated, and treatment patterns and HCRU in pts with complete data at the end of the 3-year follow-up estimated.
Results
Overall, 100 pts were included in this interim analysis; 91.0% had received only 1 prior treatment for MM. 61.0% were male, 69.0% were aged ≥65 years; median weight was 70 kg (Q1–Q3: 62–80 kg). Median time from MM diagnosis to enrollment was 2.2 years (range: 0.1–15.5 years). Most pts had relapsed (74.0%) or refractory (13.0%) MM. The majority of pts were in MM ISS stage II (31.3%) or III (29.3%). Most common previous therapies were bortezomib (74.0%) and melphalan (68.0 %). 28.0% of pts had received a stem cell transplant (all autologous), 96.4% (27 pts) were single transplantations, 2.6% (1 pt) was a double transplant.56 pts completed the 3-year follow-up period. During the follow-up period, 50.0% (28 pts) initiated a subsequent 2nd line of therapy after index therapy, 23.2% (13 pts) initiated a 3rd RR line, and 7.1% (4 pts) initiated a 4th. In 2nd, 3rd, and 4th lines, the most commonly prescribed treatments were RevDex or bortezomib-based combination therapies.The most commonly prescribed classes of medications for index therapy were immunomodulators (24 pts, 42.9%; of whom 18 pts received RevDex), and proteasome inhibitors (17 pts, 30.4%; of whom 13 pts received VelDex). 11 pts (19.6%) received chemotherapeutic agents.Time from the start of index therapy to the next line differed between RevDex and VelDex, with longer treatment durations on RevDex (16.2 months) compared to VelDex (12.5 months; Table). However, duration of subsequent lines (after progression on index therapy) was longer for pts treated with VelDex as the 1st RR line (RevDex: 9.3 months; VelDex: 15.1 months; Table). HCRU during the time spent on-therapy with the index therapy during the 3-year follow up period showed overall higher resource use for VelDex treated pts, especially for hospital consultations (Table).
Conclusion
These are the first data published describing treatment patterns and HCRU in Spanish clinical practice. The most common patterns for relapsed/refractory pts are bortezomib and lenalidomide-based schemes. Data should be interpreted with caution given the small sample size; final analyses of this study with the complete sample population will be presented at EHA.
Session topic: E-poster
Keyword(s): Cost analysis, Multiple myeloma, Practice, Treatment
Type: Publication Only
Background
The management of patients (pts) with multiple myeloma (MM) has changed considerably in recent years. Pts’ life expectancy has significantly increased, and in some cases MM is now considered a chronic disease, with pts receiving multiple lines of therapies. Real-world data on health and resource-related outcomes of different treatment patterns may help promote more efficient resource allocation within the National Health System.
Aims
To describe baseline characteristics, treatment patterns and healthcare resource utilization (HCRU) in a cohort of pts treated for relapsed refractory (RR) MM in Spain.
Methods
The PREMIERE study is a retrospective chart review study conducted in a representative cohort of pts with RRMM in Spain. Enrolled pts were aged ≥18 years, had ≥1 prior treatment for MM, and began a new line of therapy (index therapy) during the recruitment period of 1st July 2010–30th June 2012 due to relapsing or refractory disease. Pts were followed from initiation of index therapy (index date) for 3 years, or until death, loss to follow-up, or enrollment into a clinical trial for MM. Using an interim data extraction from November 30th 2015, descriptive statistics of pt characteristics at initiation of index therapy were calculated, and treatment patterns and HCRU in pts with complete data at the end of the 3-year follow-up estimated.
Results
Overall, 100 pts were included in this interim analysis; 91.0% had received only 1 prior treatment for MM. 61.0% were male, 69.0% were aged ≥65 years; median weight was 70 kg (Q1–Q3: 62–80 kg). Median time from MM diagnosis to enrollment was 2.2 years (range: 0.1–15.5 years). Most pts had relapsed (74.0%) or refractory (13.0%) MM. The majority of pts were in MM ISS stage II (31.3%) or III (29.3%). Most common previous therapies were bortezomib (74.0%) and melphalan (68.0 %). 28.0% of pts had received a stem cell transplant (all autologous), 96.4% (27 pts) were single transplantations, 2.6% (1 pt) was a double transplant.56 pts completed the 3-year follow-up period. During the follow-up period, 50.0% (28 pts) initiated a subsequent 2nd line of therapy after index therapy, 23.2% (13 pts) initiated a 3rd RR line, and 7.1% (4 pts) initiated a 4th. In 2nd, 3rd, and 4th lines, the most commonly prescribed treatments were RevDex or bortezomib-based combination therapies.The most commonly prescribed classes of medications for index therapy were immunomodulators (24 pts, 42.9%; of whom 18 pts received RevDex), and proteasome inhibitors (17 pts, 30.4%; of whom 13 pts received VelDex). 11 pts (19.6%) received chemotherapeutic agents.Time from the start of index therapy to the next line differed between RevDex and VelDex, with longer treatment durations on RevDex (16.2 months) compared to VelDex (12.5 months; Table). However, duration of subsequent lines (after progression on index therapy) was longer for pts treated with VelDex as the 1st RR line (RevDex: 9.3 months; VelDex: 15.1 months; Table). HCRU during the time spent on-therapy with the index therapy during the 3-year follow up period showed overall higher resource use for VelDex treated pts, especially for hospital consultations (Table).
Conclusion
These are the first data published describing treatment patterns and HCRU in Spanish clinical practice. The most common patterns for relapsed/refractory pts are bortezomib and lenalidomide-based schemes. Data should be interpreted with caution given the small sample size; final analyses of this study with the complete sample population will be presented at EHA.
Session topic: E-poster
Keyword(s): Cost analysis, Multiple myeloma, Practice, Treatment
Abstract: PB2097
Type: Publication Only
Background
The management of patients (pts) with multiple myeloma (MM) has changed considerably in recent years. Pts’ life expectancy has significantly increased, and in some cases MM is now considered a chronic disease, with pts receiving multiple lines of therapies. Real-world data on health and resource-related outcomes of different treatment patterns may help promote more efficient resource allocation within the National Health System.
Aims
To describe baseline characteristics, treatment patterns and healthcare resource utilization (HCRU) in a cohort of pts treated for relapsed refractory (RR) MM in Spain.
Methods
The PREMIERE study is a retrospective chart review study conducted in a representative cohort of pts with RRMM in Spain. Enrolled pts were aged ≥18 years, had ≥1 prior treatment for MM, and began a new line of therapy (index therapy) during the recruitment period of 1st July 2010–30th June 2012 due to relapsing or refractory disease. Pts were followed from initiation of index therapy (index date) for 3 years, or until death, loss to follow-up, or enrollment into a clinical trial for MM. Using an interim data extraction from November 30th 2015, descriptive statistics of pt characteristics at initiation of index therapy were calculated, and treatment patterns and HCRU in pts with complete data at the end of the 3-year follow-up estimated.
Results
Overall, 100 pts were included in this interim analysis; 91.0% had received only 1 prior treatment for MM. 61.0% were male, 69.0% were aged ≥65 years; median weight was 70 kg (Q1–Q3: 62–80 kg). Median time from MM diagnosis to enrollment was 2.2 years (range: 0.1–15.5 years). Most pts had relapsed (74.0%) or refractory (13.0%) MM. The majority of pts were in MM ISS stage II (31.3%) or III (29.3%). Most common previous therapies were bortezomib (74.0%) and melphalan (68.0 %). 28.0% of pts had received a stem cell transplant (all autologous), 96.4% (27 pts) were single transplantations, 2.6% (1 pt) was a double transplant.56 pts completed the 3-year follow-up period. During the follow-up period, 50.0% (28 pts) initiated a subsequent 2nd line of therapy after index therapy, 23.2% (13 pts) initiated a 3rd RR line, and 7.1% (4 pts) initiated a 4th. In 2nd, 3rd, and 4th lines, the most commonly prescribed treatments were RevDex or bortezomib-based combination therapies.The most commonly prescribed classes of medications for index therapy were immunomodulators (24 pts, 42.9%; of whom 18 pts received RevDex), and proteasome inhibitors (17 pts, 30.4%; of whom 13 pts received VelDex). 11 pts (19.6%) received chemotherapeutic agents.Time from the start of index therapy to the next line differed between RevDex and VelDex, with longer treatment durations on RevDex (16.2 months) compared to VelDex (12.5 months; Table). However, duration of subsequent lines (after progression on index therapy) was longer for pts treated with VelDex as the 1st RR line (RevDex: 9.3 months; VelDex: 15.1 months; Table). HCRU during the time spent on-therapy with the index therapy during the 3-year follow up period showed overall higher resource use for VelDex treated pts, especially for hospital consultations (Table).
Conclusion
These are the first data published describing treatment patterns and HCRU in Spanish clinical practice. The most common patterns for relapsed/refractory pts are bortezomib and lenalidomide-based schemes. Data should be interpreted with caution given the small sample size; final analyses of this study with the complete sample population will be presented at EHA.
Session topic: E-poster
Keyword(s): Cost analysis, Multiple myeloma, Practice, Treatment
Type: Publication Only
Background
The management of patients (pts) with multiple myeloma (MM) has changed considerably in recent years. Pts’ life expectancy has significantly increased, and in some cases MM is now considered a chronic disease, with pts receiving multiple lines of therapies. Real-world data on health and resource-related outcomes of different treatment patterns may help promote more efficient resource allocation within the National Health System.
Aims
To describe baseline characteristics, treatment patterns and healthcare resource utilization (HCRU) in a cohort of pts treated for relapsed refractory (RR) MM in Spain.
Methods
The PREMIERE study is a retrospective chart review study conducted in a representative cohort of pts with RRMM in Spain. Enrolled pts were aged ≥18 years, had ≥1 prior treatment for MM, and began a new line of therapy (index therapy) during the recruitment period of 1st July 2010–30th June 2012 due to relapsing or refractory disease. Pts were followed from initiation of index therapy (index date) for 3 years, or until death, loss to follow-up, or enrollment into a clinical trial for MM. Using an interim data extraction from November 30th 2015, descriptive statistics of pt characteristics at initiation of index therapy were calculated, and treatment patterns and HCRU in pts with complete data at the end of the 3-year follow-up estimated.
Results
Overall, 100 pts were included in this interim analysis; 91.0% had received only 1 prior treatment for MM. 61.0% were male, 69.0% were aged ≥65 years; median weight was 70 kg (Q1–Q3: 62–80 kg). Median time from MM diagnosis to enrollment was 2.2 years (range: 0.1–15.5 years). Most pts had relapsed (74.0%) or refractory (13.0%) MM. The majority of pts were in MM ISS stage II (31.3%) or III (29.3%). Most common previous therapies were bortezomib (74.0%) and melphalan (68.0 %). 28.0% of pts had received a stem cell transplant (all autologous), 96.4% (27 pts) were single transplantations, 2.6% (1 pt) was a double transplant.56 pts completed the 3-year follow-up period. During the follow-up period, 50.0% (28 pts) initiated a subsequent 2nd line of therapy after index therapy, 23.2% (13 pts) initiated a 3rd RR line, and 7.1% (4 pts) initiated a 4th. In 2nd, 3rd, and 4th lines, the most commonly prescribed treatments were RevDex or bortezomib-based combination therapies.The most commonly prescribed classes of medications for index therapy were immunomodulators (24 pts, 42.9%; of whom 18 pts received RevDex), and proteasome inhibitors (17 pts, 30.4%; of whom 13 pts received VelDex). 11 pts (19.6%) received chemotherapeutic agents.Time from the start of index therapy to the next line differed between RevDex and VelDex, with longer treatment durations on RevDex (16.2 months) compared to VelDex (12.5 months; Table). However, duration of subsequent lines (after progression on index therapy) was longer for pts treated with VelDex as the 1st RR line (RevDex: 9.3 months; VelDex: 15.1 months; Table). HCRU during the time spent on-therapy with the index therapy during the 3-year follow up period showed overall higher resource use for VelDex treated pts, especially for hospital consultations (Table).
Conclusion
These are the first data published describing treatment patterns and HCRU in Spanish clinical practice. The most common patterns for relapsed/refractory pts are bortezomib and lenalidomide-based schemes. Data should be interpreted with caution given the small sample size; final analyses of this study with the complete sample population will be presented at EHA.
Session topic: E-poster
Keyword(s): Cost analysis, Multiple myeloma, Practice, Treatment
{{ help_message }}
{{filter}}